Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-04-08
2000-02-15
Spivack, Phyllis G.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514422, A61K 31445, A61K 3138
Patent
active
060253738
ABSTRACT:
The invention is related to reducing fibrinogen in a human by administering a 2-aroyl-3-arylbenzo[b]thiophene compound.
REFERENCES:
patent: 4133814 (1979-01-01), Jones et al.
patent: 4380635 (1983-04-01), Peters
patent: 4418068 (1983-11-01), Jones
patent: 5075321 (1991-12-01), Schreiber
patent: 5441965 (1995-08-01), Sall et al.
patent: 5445941 (1995-08-01), Yang
patent: 5476862 (1995-12-01), Calnek et al.
patent: 5482949 (1996-01-01), Black et al.
patent: 5508292 (1996-04-01), Sall et al.
patent: 5731328 (1998-03-01), Berg et al.
R. Young et al., "Raloxifene is a Tissue-Selective Agonist/Antagonist That Functions through the Etrogen Receptor", Annals of the New York Academy of Sciences, 761:355-60, 1995.
Walsh et al., "Effects of Raloxifene on Serum Lipids and Coagulation Factors in Healthy Postmenopausal Women", JAMA 279:18 1998.
"First Phase III Results With Raloxifene" Database Dialog File 129: Phind Accession & Scrip 2240, 1997.
"Raloxifene Lilly Recommended for Approval" Database Dialog File 445: IMS World R7D Focus, Xp002074925 & R&D Focus Drug News, 1997.
"Raloxifene Lilly Clinical Data" Databse Dialog File 445: IMS World R&D Focus, Xp002074926 & R&D Focus Drug News, Jun. 1997.
D. Somjen et al., "Tissue Selective Action of Tamoxifen Methiodide, Raloxifene and TAmoxifen on Creatine Kinase B Activity In Vitro and In Vivo", J. Steriod Biochem. Molec. vol. 59:5/6:389-396, 1996.
Zukcerman et al., "Inhibition of LDL oxidation and myleoperoxidase dependent tyrosyl radical formation by the selective estrogen receptor modulator raloxifene (LY139481 HCL)" Atherosclerosis 126:65-75, 1996.
Draper et al., "A Controlled Trial of Raloxifene (LY139481) HCI: Impact on Bone Turnover and Serum Lipid Profile in Helathy Postmenopausal Women", Journal of Bone and Mineral Research, 11:16, 1996.
Grey, et al., "The Effect of the Anti-Estrogen Tamoxifen on Cardiovascular Risk Factors in Normal Postmenopausal Women", Journal of Clinical Endocrinology and Metabolism, 80:11, 1995.
Draper et al., "Effects of Raloxifene (LY139481 HC1) on Biochemical Markers of Bone and Lipid Metabolism i Healthy Postmenopausal Women", Hong Kong, Fourth Int'l Symp. on Osteoporosis, Mar. 29, 1993.
Bryant et al., "Protection from Bone Loss and Lowering of Serum Cholesterol in the Absence of Uterine Stimulation in Ovariectomized Rats", Am Soc. Bone & Min. Res., Tampa, Sept. 18-22, 1993.
Bryant et al., "Raloxifene is a Tissue Specific Estrogen Agonist", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Frolick et al., "In Vivo and In Vitro Metabolism of Raloxifene", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Glasebrook et al., "Multiple Binding Sites for the Anti-estrogen Raloxifene", Am Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Hock et al., "Combination of Raloxifene and Human Parathyoid Hormone 1-34; Increased Femur Bone Mass in Young Ovariectomized (OVX) Rats", Am. Soc. Bone & Min. Res., Tampa, Sep. 18-22, 1993.
Sato et al., "DEXA Analysis of Raloxifene Effects on the Bones From Ovariectomized Rats", Am. Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Yang et al., "Raloxifene an Anti-Estrogen, Simulates the Effects of Estrogen in Inhibiting Bone Resorption Through Regulating TGFB-3 Expression in Bone;".Am Soc. for Bone and Min. Res., Tampa, Sep. 18-22, 1993.
Black et al., "Distinct, Structure-Related Profiles of Estrogenic and Anti-Estrogenic Activity in the Tamoxifen and LY117018 Series;" The Endocrine Society, Abstract 1982.
Black et al., "Uterine Bioassay of Tamoxifen, Trioxifene, and New Estrogen Antagonist (LY117018) in Rats and Mice," Life Sciences, 26:1980, 1453-1458.
Black et al., "Differential Interaction of Antiestrogens with Cytosol Estrogen Receptors," Molecular and Cellular Endocrinology, 22:1981, 95-103.
Black et al., "Evidence for Biological Action of the Antiestrogens LY117018 and Tamoxifen by Different Mechanisms," Endocrinology 109;1981, 987-989.
Black, L.J. "Biological Actions and Binding Properites of a New Estrogen Antagosist LY117018," In: Homone Antagonists, 129-82, 1982 (M.K. Agarwal ed.) Walter de Gruyter and Co., Berlin New York.
Black et al., LY156758: A Unique Antiestrogen Displaying High Affinity for Estrogen Receptors, Negligible Estrogenic Activity and Near-Total Estrogen Antagonism in Vivo. Presented at the Fifth Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, Nov. 5-6, 1982.
Black et al., The Antiestrogenic Action of LY139481: Species Uniformity Duration of Action and Kinetics of 3H-LY139481 Distribution In Vivo. Sixty-fifth Annual Meeting of the Endocrine Society, San Antonio, Texas, June 8-10, 1983, abs. 93.
Black et al., Antogonism of Estrogen Action with a New benzothiophene Derived Antiestrogen, Life Sciences, 32:1983. 1031-1036.
Black et al., The Relationship of the Antiestrogenic Efficacy of LY156758 to its Pharmacokinetics and Metabolism Following Oral Administration to Adult Ovariectomized Rats, Seventh International Congress of Endocrinology, Quebec City, Canada, Jul. 1-7, 1984, abs. 323.
Black et al., Synthesis and Antiestrogenic Activity of [3,4-Dihydro-2(4-methoxyphenyl)-1-napthalenyl] [4-[2-pyrrolidinyl) ethoxyl]-phenyl] methanone, methanesulfonic acid salt, Journal of Medicinal Chemistry 22;1979, 962-966.
Dina M. Bitar et al., Suppression of Experimental Autoimmune Encephalomyelitis by the Oral Administration of Myelin Basic Protein, Cellular Immunology 112, 364-370, 1988.
Paul J. Higgins, et al., Suppression of Experimental Autoimmune Encephalomyelitis by Oral Administration of Myelin Basic Protein and its Fragments, The Journal of Immunology, vol. 140(2), 440-445, Jan. 15, 1988.
Oral Tolerance to Myelin Basic Protein and Natural Recovery from Experimental Autoimmune Encephalomyelitis Are Associated with Downregulation of Inflammatory Cytokines and Differential Upregulation of Transforming Growth Factor .beta., Intrerleukin 4, and Prostaglandin E Expression In the Brain, J. Exp. Med., vol., 176, 1355-1364, Nov. 1992.
C.D. Jones, et al. Antiestrogens. 2..sup.1 Structure-Activity Studies in a Series of 3-Aroyl-2-arylbenzo{b}thiophene Derivatives Leading to [6-Hyddroxy-2-(4-hydroxyphenyl)benzo{b}thien-3-yl][4-[2-(1-piperidinyl)eth oxy]-phenyl]methanone Hydrochloride (LY156758), A remarkably Effective Estrogen Antagonist With Only Minimal Intrinsic Estrogenicity, J. Med. Chem., 1984, 27, 1057-1066.
A Hendrick, et al., Tamoxifen and Thromboembolism, Journal of the American Medical Association, vol. 243, No. 6, Feb. 8, 1980.
Radwanska, E., The Role of Reproductive Hormones in Vascular Diseases and Hypertension, Steriods, 58(12), 605, Dec. 1993.
Pfilger, et al., Acta Med. Austriaca, 18(3), 68-72, 1991.
Boureaux William R.
Eli Lilly and Company
Sales James J.
Spivack Phyllis G.
LandOfFree
Methods for reducing fibrinogen does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for reducing fibrinogen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for reducing fibrinogen will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1906207